VivoSeq
Other

Spastic Paraplegia

6

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Spastic paraplegia is an early-stage landscape with 6 programs across 4 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elpida Therapeutics SPC, Johnson & Johnson. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 1E

Elpida Therapeutics SPC

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Recruiting1 · 25%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Calcium Folinate Treatment of Spastic Paraplegia 56
Recruiting·SShanghai 6th People's Hospital·Phase 1·NCT06478238·10 enrolled
Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT02314208·12 enrolled
Testing Miglustat Administration in Subjects With Spastic Paraplegia 11
Completed·IIRCCS Fondazione Stella Maris·Phase 2·NCT04768166·10 enrolled
Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50
Active, not recruiting·TThe Hospital for Sick Children·Phase 1·NCT06069687·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)